Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication INREBIC ® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). INREBIC is a kinase inhibitor indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) ( 1 ). FDA label
Also known as BMS-847943
Fedratinib · 2 trials · 3 indications
Percentage of participants who have ≥ 35% spleen volume reduction (SVR) at end of cycle 6 A Cochran-Mantel-Haenszel (CMH) test to adjust for planned stratification factors (spleen size by palpation, platelet counts and refractory/relapsed or intolerance to ruxolitinib treatment). The RRs and 95% confidence intervals (CI) will be provided for each arm as well as for the difference in RRs and 95% confidence interval of the difference for fedratinib to BAT.
is the highest dose that causes DLTs in not more than 33% of the subjects treated with fedratinib in the first cycle with at least 3 evaluable subjects treated at this dose.
is a recommended Phase 2 dose that is determined as safe and tolerable by the Safety Review Committee based on the data from the first cycle with at least 3 evaluable subjects treated at each dose of the Phase 1 part.
Proportion of subjects who have ≥ 35% SVR at end of Cycle 6 from baseline
| Arm | Type | Description |
|---|---|---|
| Fedratinib 400mg/day | EXPERIMENTAL | Will include up to 128 subjects receiving fedratinib 400 mg self-administered Investigational Product (IP) on an outpatient basis, once daily preferably together with food during an evening meal at the same time each day in consecutive 4-week (28-day) cycles. |
| Best Available Therapy (BAT) | ACTIVE_COMPARATOR | Best-available Investigator-selected therapy included a number of available compounds to treat MF and/or its symptoms and was chosen by the investigator for each subject. Therapy changed at different times during the treatment period. No investigational agents (e.g. not approved for the treatment of any indication) were allowed. BAT also included the choice of no treatment. |
| Fedratinib Administration | EXPERIMENTAL | The fedratinib dose is 300 or 400 mg/day PO (3 or 4 x 100 mg capsules) to be self-administered orally once daily continuously on an outpatient basis, preferably together with food during an evening meal, the same time each day. |
| Name | Type | Description |
|---|---|---|
| FEDRATINIB | DRUG | A potent and selective inhibitor of JAK2 kinase activity |
| Best Available Therapy (BAT) | DRUG | Best available therapy (BAT) |
Inclusion Criteria: 1. Subject is at least 18 years of age at the time of signing the informed consent form (ICF) 2. Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Score (PS) of 0, 1 or 2 3. Subject has diagnosis of primary myelofibrosis (PMF) according to the 2016 World Healt...
Fedratinib is a small-molecule inhibitor studied for primary myelofibrosis, including DIPSS intermediate- or high-risk disease, as well as post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. It has been evaluated in patients previously treated with ruxolitinib and in Japanese subjects with these myelofibrosis subtypes.
Fedratinib targets JAK2 and FLT3, and it is classified as an inhibitor of these kinases. JAK2 is the molecular target named for the compound, with FLT3 also listed as a target. Its development in myelofibrosis centers on this kinase inhibition profile.
Fedratinib is developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is the sponsor associated with the clinical development program for fedratinib in myelofibrosis.
Fedratinib has reached Phase 3 development in primary myelofibrosis. The Phase 3 study in the program is listed as completed. Fedratinib is an investigational agent in clinical development, and the available program information does not indicate marketing approval.
Fedratinib has been studied in two completed trials. NCT03952039 is a Phase 3 study comparing fedratinib with best available therapy in previously ruxolitinib-treated myelofibrosis patients, enrolling 202 participants across Europe, Asia and Australia. NCT04446650 is a Phase 1/Phase 2 study in Japanese subjects with myelofibrosis, enrolling 31 participants.
The fedratinib clinical program enrolled 233 participants across its two completed trials. The Phase 3 study NCT03952039 accounted for 202 of these, and the Phase 1/Phase 2 Japanese study NCT04446650 enrolled 31. The Phase 3 trial was randomized and active-controlled.